Siegfried Holding AG (CHIX:SFZNZ) ROCE % : 12.71% (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Siegfried Holding AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Siegfried Holding AG's annualized ROCE % for the quarter that ended in Jun. 2024 was 12.71%.

Siegfried Holding AG ROCE % Historical Data

The historical data trend for Siegfried Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Siegfried Holding AG ROCE % Chart

Siegfried Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

6.00

8.03

10.66

15.75

10.86

Siegfried Holding AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															12.39	19.48	10.78	11.01	12.71

Siegfried Holding AG ROCE % Calculation

Siegfried Holding AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	159.676	/	( ( (1793.2 - 317.594)	+	(1861.505 - 397.8) )	/ 2 )
	=	159.676	/	( (1475.606	+	1463.705)	/ 2 )
	=	159.676	/	1469.6555
	=	10.86 %

Siegfried Holding AG's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	189.582	/	( ( (1861.505 - 397.8)	+	(1877.78 - 357.602) )	/ 2 )
	=	189.582	/	( ( 1463.705	+	1520.178 )	/ 2 )
	=	189.582	/	1491.9415
	=	12.71 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Siegfried Holding AG (CHIX:SFZNz) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Siegfried Holding AG ROCE % Related Terms

Thank you for viewing the detailed overview of Siegfried Holding AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Siegfried Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Siegfried Holding AG (CHIX:SFZNz) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0QQO:UK SFZN:Switzerland

Address

Untere Bruehlstrasse 4, Zofingen, CHE, CH-4800

Website

https://www.siegfried.ch

Siegfried Holding is a global contract development and manufacturing organization, or CDMO. Siegfried derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. Siegfried provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 12 production sites on three continents.

Siegfried Holding AG Headlines

No Headlines